Retatrutide Delivers Unprecedented Weight Loss in Phase 3 Trial
In a major clinical trial, the investigational weight-loss drug retatrutide helped adults with type 2 diabetes lose nearly a fifth of their body weight, according to results published in The Lancet and presented at the European Association for the Study of Diabetes. The 80-week phase 3 trial, called TRIUMPH-2, enrolled 1,152 adults with overweight or obesity and type 2 diabetes across multiple sites. Participants receiving the highest dose of retatrutide (12 mg weekly) lost an average of 18.8% of their starting weight, compared with just 5.1% for those on placebo. Nearly half (47%) of those on the 12 mg dose achieved at least 20% weight loss, versus 6% on placebo. The drug, developed by Eli Lilly, is a triple agonist that activates three hormone receptors: GIP, GLP-1, and glucagon—a novelty that appears to amplify both weight loss and blood sugar control.
A Breakthrough for a Difficult-to-Treat Population
The trial specifically targeted people with type 2 diabetes, a group that has historically responded less well to obesity medications than those without diabetes. A meta-analysis of 45 studies found that non-diabetic individuals lost 15.7% of their body weight on GLP-1 receptor agonists at 12 months, while diabetic patients lost only 5.1%—a 2.5- to 4-fold difference. Retatrutide’s results suggest that gap may be closing. “There is an unmet need for more efficacious weight reduction in individuals with type 2 diabetes,” the researchers noted. The drug also improved markers of cardiovascular and metabolic health, though gastrointestinal side effects like nausea and diarrhea were more common than with placebo.
Bootleg Retatrutide Linked to Two Deaths
Just as the scientific community celebrates retatrutide’s promise, a darker side of the story has emerged. CBS News reported that the U.S. Food and Drug Administration (FDA) received reports of two deaths connected to bootleg versions of the drug, which is not yet approved for any use. The first death occurred in July: a 41-year-old woman with obesity went into cardiac arrest after obtaining retatrutide “from an unreliable source.” In September, a 49-year-old patient died after a licensed nurse convinced her to buy retatrutide from an online peptide vendor; she suffered severe dehydration, malnutrition, and cardiac arrest. Both cases were submitted to the FDA’s Adverse Event Reporting System, though the details remain unverified and it is unclear whether the drug itself was to blame. “It is concerning because of the breakdown of our drug-approval process in the United States,” said Pieter Cohen, an associate professor at Harvard Medical School. “The FDA should do whatever it possibly could do to get their hands on the actual drug that was injected by both of these patients.” The reports highlight a booming illicit market for unapproved weight-loss drugs, with retatrutide widely available in health spas, wellness websites, and even convenience stores, according to previous CBS News investigations.
The Perils of a Gray Market
Federal law prohibits the commercial sale of unapproved drugs, but that hasn’t stopped vendors from selling imitation versions of retatrutide online at a scale with no modern precedent. Some sellers have been aided by an independent, blue-chip certification that gives them the appearance of legitimacy and the ability to advertise on social media. Dozens of medical professionals have openly promoted access to the drug, further blurring the lines between legitimate clinical research and dangerous self-medication. The two deaths are the first public accounts in the U.S. alleging that unauthorized use of retatrutide—or products claiming to contain it—played a role in a patient’s death. The FDA declined to say whether it has verified any of the information in either report, but said it reviews adverse event reports and gathers additional information when needed.
The Science Behind the Hype
Retatrutide belongs to a new class of drugs called triple agonists, which target three hormone receptors simultaneously. Semaglutide (Ozempic, Wegovy) targets only GLP-1; tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP. Retatrutide adds glucagon, a hormone that increases energy expenditure and fat burning. “We call this the triple G agonist,” said Holly Lofton, MD, director of the medical weight management program at NYU Langone Health and a principal investigator in a retatrutide clinical trial. “The additional benefit of glucagon agonism, beyond tirzepatide’s GLP-1/GIP agonism, is greater delay in gastric emptying and improved fat-cell metabolism.” In short, it’s designed to be stronger and faster-acting than its predecessors. That appears to be particularly true for weight loss, said Jennifer Manne-Goehler, MD, an assistant professor of medicine at Harvard Medical School. However, the stronger effect may also come with stronger side effects, including more nausea and diarrhea, which were observed in the trial.
Implications for Metabolic Trial Design
The TRIUMPH-2 data has forced a reckoning with how metabolic trials are designed, according to a commentary in The Clinical Trial Vanguard. For years, sponsors assumed that type 2 diabetes would always blunt the weight-loss signal of obesity drugs. The new results challenge that assumption and suggest that future trials may need to rethink their endpoints and patient populations. The trial’s success could also accelerate the development of other triple agonists and combination therapies, as companies race to capture a share of the lucrative weight-loss market. But the shadow of illicit use and safety concerns looms large, especially as the drug remains unapproved. Eli Lilly has not commented on the reported deaths, but the company continues to sponsor clinical trials and has emphasized that retatrutide is not available outside of those trials.
A Double-Edged Sword
The retatrutide story encapsulates both the promise and peril of modern weight-loss medicine. On one hand, the drug represents a potential breakthrough for people with type 2 diabetes and obesity, offering weight loss that rivals bariatric surgery. On the other hand, the unregulated online market for the drug has already led to at least two deaths, underscoring the dangers of self-medicating with unapproved substances. The FDA has not approved retatrutide, and it is generally not supposed to be available outside of clinical trials. Yet the demand is so high that a thriving black market has emerged, fueled by social media promotion and a lack of regulatory oversight. As the scientific community celebrates the trial results, regulators and law enforcement face a growing challenge: how to protect patients from the risks of bootleg drugs while ensuring that legitimate research can continue. The balance is delicate, and the stakes could not be higher.
What’s Next for Retatrutide?
Eli Lilly is expected to seek FDA approval for retatrutide in the coming years, but the timeline remains uncertain. Additional phase 3 trials are ongoing, and the company will need to submit a comprehensive safety profile, including data on cardiovascular outcomes. The reported deaths from bootleg versions may complicate the approval process, as regulators will likely scrutinize the drug’s safety profile even more closely. Meanwhile, patients and doctors are left to navigate a landscape where a promising but unapproved drug is just a click away—and where the consequences of misinformation can be fatal. As the Lancet commentary noted, the TRIUMPH-2 trial “stress-tested a structural assumption” about diabetes and weight loss. Now, the real-world consequences of that stress test are unfolding outside the controlled environment of clinical research.
Comments